Technical Analysis for ONC - Oncolytics Biotech Inc.

Grade Last Price % Change Price Change
C 1.440 0.70% 0.010
ONC closed up 0.7 percent on Friday, April 19, 2024, on 28 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 3
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Down

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish 0.70%
Narrow Range Bar Range Contraction 0.70%
Stochastic Reached Oversold Weakness 0.70%
Oversold Stochastic Weakness 0.70%
Fell Below 20 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 19 hours ago
Rose Above 50 DMA about 19 hours ago
50 DMA Resistance about 22 hours ago
Up 1% about 22 hours ago
50 DMA Resistance 1 day ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Oncolytics Biotech Inc. Description

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.


Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Clinic Cancer RTT Therapy Clinical Trial Oncology Lung Cancer Blastoma Chemotherapy Non Small Cell Lung Cancer Glioblastoma

Is ONC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 4.49
52 Week Low 1.2
Average Volume 82,789
200-Day Moving Average 2.233
50-Day Moving Average 1.440
20-Day Moving Average 1.476
10-Day Moving Average 1.507
Average True Range 0.082
RSI (14) 46.81
ADX 19.15
+DI 18.274
-DI 16.875
Chandelier Exit (Long, 3 ATRs) 1.503
Chandelier Exit (Short, 3 ATRs) 1.607
Upper Bollinger Bands 1.618
Lower Bollinger Band 1.334
Percent B (%b) 0.37
BandWidth 19.241
MACD Line 0.007
MACD Signal Line 0.017
MACD Histogram -0.0104
Fundamentals Value
Market Cap 62.35 Million
Num Shares 43.3 Million
EPS -1.02
Price-to-Earnings (P/E) Ratio -1.42
Price-to-Sales 0.00
Price-to-Book 7.41
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.485
Resistance 3 (R3) 1.483 1.467 1.478
Resistance 2 (R2) 1.467 1.455 1.468 1.475
Resistance 1 (R1) 1.453 1.448 1.460 1.455 1.472
Pivot Point 1.437 1.437 1.440 1.438 1.437
Support 1 (S1) 1.423 1.425 1.430 1.425 1.408
Support 2 (S2) 1.407 1.418 1.408 1.405
Support 3 (S3) 1.393 1.407 1.403
Support 4 (S4) 1.395